Patents Examined by Mary E. Mosher
  • Functional influenza virus-like particles (VLPs)
    Patent number: 7763450
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: July 27, 2010
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • Replikin peptides in rapid replication of glioma cells and in influenza epidemics
    Patent number: 7758863
    Abstract: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: July 20, 2010
    Inventors: Samuel Bogoch, Elenore S. Bogoch
  • Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
    Patent number: 7758866
    Abstract: An immunogenic composition and methods for producing said composition, the composition comprising VLPs from HPV 16 and 18 and at least one other HPV cancer type, the other cancer type being selected from the list consisting of HPV types 31, 45 and 52, wherein the dose of the VLP of the at least one other cancer types is reduced relative to that of HPV 16 or 18.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: July 20, 2010
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Serge Debrus, Marie-Therese Martin, Robert John Stephen, Jean Stephenne, Martine Anne Cecile Wettendorff
  • Cationic steroid antimicrobial compositions and methods of use
    Patent number: 7754705
    Abstract: The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with poxvirus infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of poxvirus infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: July 13, 2010
    Assignees: Brigham Young University, National Jewish Medical and Research Center
    Inventors: Paul B. Savage, Donald Y Leung
  • Safe mutant viral vaccines
    Patent number: 7754222
    Abstract: The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: July 13, 2010
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: Siao-Kun Wan Welch, Jay Gregory Calvert, Michael K O'Hara, Xuemei Cao
  • Detection of intact recombinant viruses
    Patent number: 7754421
    Abstract: In accordance with the present invention, there is provided a new method for detection and quantification of virus and viral particles, comprising the step of labeling the nucleic acids of an intact virus or viral particle with a dye that emits fluorescence once complexed with the nucleic acids and detecting the virus or viral particle with a chromatograph equipped with a fluorescence detector.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: July 13, 2010
    Assignee: National Research Council of Canada
    Inventors: Julia Transfiguracion, Amine Kamen
  • Cellular permissivity factor for viruses and uses thereof
    Patent number: 7754464
    Abstract: The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: July 13, 2010
    Assignee: Pharmacia and Upjohn Company, LLC
    Inventors: Jay Gregory Calvert, Shelly Shields, David E Slade, Siao-Kun Welch
  • Isolated recombinant vaccinia virus complement control protein (hrVCP) polypeptide
    Patent number: 7749963
    Abstract: An isolated recombinant vaccinia virus complement control protein (hrVCP) polypeptide comprises a modified amino acid sequence comprising one or more amino acid substitutions to an amino acid sequence as set forth in SEQ ID NO: 2. The hrVCP polypeptide exhibits a complement activation regulatory activity greater than a complement activation regulatory activity of a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2. The one or more amino acid substitutions are selected from the group consisting of H98Y, E102K, E108K, E120K, and combinations thereof.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: July 6, 2010
    Inventor: Girish J. Kotwal
  • Viral vectors and their use in therapeutic methods
    Patent number: 7749745
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: July 6, 2010
    Assignees: Georgetown University, The General Hospital Corporation, MediGene, Inc.
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
    Patent number: 7744898
    Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
    Type: Grant
    Filed: September 8, 2005
    Date of Patent: June 29, 2010
    Assignee: The Scripps Research Institute
    Inventor: Francis V. Chisari
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 7744901
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: June 29, 2010
    Assignees: MedImmune, LLC, National Institute of Health
    Inventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
  • Recombinant vaccine against West Nile Virus
    Patent number: 7740863
    Abstract: An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: June 22, 2010
    Assignee: Merial
    Inventors: Sheena May Loosmore, Jean-Christophe Francis Audonnet, Jules Maarten Minke
  • Amplification of HIV-1 sequences for detection of sequences associated with drug-resistance mutations
    Patent number: 7741027
    Abstract: Sequences of nucleic acid oligonucleotides for amplifying different portions of gag and pol genes of HIV-1 and for detecting such amplified nucleic acid sequences are disclosed. Methods of amplifying and detecting HIV-1 nucleic acid in a biological sample using the amplification oligonucleotides specific for gag and pol target sequences are disclosed.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: June 22, 2010
    Assignees: Gen-Probe Incorporated, BioMerieux S.A.
    Inventors: Yeasing Y. Yang, Steven T. Brentano, Odile Babola, Nathalie Tran, Guy Vernet
  • Cooperative reporter systems, components, and methods for analyte detection
    Patent number: 7741128
    Abstract: The present invention relates to methods and compositions to detect analytes in a sample using antibody molecules that are transformed into nanoscale “self-signaling” biosensors. It relates in particular to those methods and compositions that provide for single-step detection of target analytes without the need for labor-intensive steps necessary in conventional assays.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: June 22, 2010
    Assignee: University of Hawaii
    Inventor: Wei Wen Su
  • Ultra high affinity neutralizing antibodies
    Patent number: 7740851
    Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: June 22, 2010
    Assignee: MedImmune, LLC
    Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
  • Binding molecules capable of neutralizing rabies virus and uses thereof
    Patent number: 7740852
    Abstract: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 22, 2010
    Assignee: Crucell Holland B.V.
    Inventors: Alexander Berthold Hendrik Bakker, Willem Egbert Marissen, Robert Arjen Kramer, Cornelis Adriaan De Kruif
  • Immunogenic proteoliposomes, and uses thereof
    Patent number: 7741024
    Abstract: An immunogenic proteoliposome containing a transmembrane protein or oligomeric complexes containing such proteins, including viral envelope glycoproteins, in a lipid membrane around an elliptoid or spherical shape. The shape preferably also contains an attractant such as streptavidin or avidin and the lipid membrane contains a moiety that binds to the attractant such as biotin. The immunogenic transmembrane protein is bound to a ligand which is anchored in the shape. Methods for making the immunogenic proteoliposomes are provided. uses of the proteoliposome are described, including their use as immunogens to elicit immune reaction, and their use in screening assays, including their use as antigens to screen antibody libraries, as well as for drug screening and the identification of ligands.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: June 22, 2010
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Richard T Wyatt, Joseph G Sodroski, Tajib Mirzabekov, Christoph Grundner
  • Composition and method for preventing or treating a virus infection
    Patent number: 7740860
    Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: June 22, 2010
    Assignee: The Wistar Institute
    Inventors: Walter Gerhard, Laszlo Otvos, Jr.
  • Anti-RSV G protein antibodies
    Patent number: 7736648
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: June 15, 2010
    Assignee: Trellis Bioscience, Inc.
    Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • Topical delivery of vaccines
    Patent number: 7731968
    Abstract: The present invention provides improved methods for delivery of substances into the skin. It has been discovered that delivery of substances such as nucleic acids, amino acids, amino acid derivatives, peptides and polypeptides simultaneously with abrasion of the skin enhances delivery and the biological response as compared to application of the substance to previously abraded skin.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: June 8, 2010
    Assignee: Becton, Dickinson and Company
    Inventors: John A. Mikszta, John M. Brittingham, Jason Alarcon, Ronald J. Pettis, John P. Dekker, III